Background Based on preclinical synergy in murine choices, we completed a
Background Based on preclinical synergy in murine choices, we completed a stage I trial to look for the maximum tolerated dose (MTD), toxicities, pharmacokinetics, and biomarkers of response for the mix of BKM120, a PI3K inhibitor, and olaparib, a PARP inhibitor. acquired a germline mutation (gwild-type (gmutations, PI3K pathway activation, and zero DNA damage fix … [Read more…]